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Abstract 
Many long-term, follow-up studies have shown that steroids are effective in patients with 
myasthenia gravis (MG) who have undergone thymectomy. However, few long-term 
studies have documented the response of MG to steroids alone. We describe two 
patients who successfully resolved the symptoms of MG without myasthenic crisis or 
serious side effects by steroid treatment without thymectomy or other alternative 
therapies for more than 19 years. Our experiences raise an open question of the role of 
thymectomy or steroid treatment alone, especially in MG patients without thymoma. 
 
Introduction 
Steroids have been widely used for the treatment of myasthenia gravis (MG) since the 
1950s, being first introduced in 1935 [1]. Steroids are often considered as an alternative 
means of immunotherapy because other immunologic treatments such as plasma 
exchange, intravenous immunoglobulins, or immunosuppressive agents are expensive 
and associated with potentially serious adverse effects. Many long-term, follow-up studies 
have shown that steroids are effective in patients with MG who have undergone 
thymectomy or who concurrently receive immunosuppressive agents or plasma exchange. 
However, few long-term studies have documented the response of MG to steroids alone 
[2–4]. It is therefore of great interest whether monotherapy with steroids is effective in 
MG. We describe two patients with generalized MG whose disease was controlled for 
more than 19 years by treatment with steroids alone. Case Rep Neurol 2011;3:239–241 
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Case Reports 
Patient 1 
In September 2002, a 34-year-old woman with a history of MG visited our hospital. She was not 
receiving medication. At 6 years of age, a neurologist was consulted because of bilateral ptosis and 
diplopia. The results of an edrophonium test were positive. The patient was given a diagnosis of MG 
and administered oral prednisolone, which reduced the disease severity. Similar symptoms often 
developed subsequently, and the dose of prednisolone was adjusted as required. At 8 years of age, the 
patient presented with general weakness with respiratory dysfunction and received 3 courses of pulse 
therapy with intravenous methylprednisolone. At the age of 12 years, oral prednisolone was 
discontinued. She gave birth without symptoms of MG at the age of 33 years. In January 2004, she 
noticed diplopia and ptosis with general fatigue, particularity in the evening. Moderately limited ocular 
motility was present. There was no other neurological deficit. Grasping power decreased from 12 kg to 6 
kg after she gripped the hand dynamometer 5 times. The results of a routine serum laboratory workup 
were normal. The anti-acetylcholine receptor-binding antibody titer was 2.3 nmol/l (>0.2 nmol/l; 
normal upper limit). A computed tomographic scan of the chest showed no evidence of mediastinal 
thymoma. Cholinesterase inhibitor treatment was started. In September 2004, she had difficulty in 
swallowing saliva and holding her child. Daily oral prednisolone (5 to 25 mg/day) was started in 
combination with a fixed dose of cholinesterase inhibitor. The severity of disease improved. 
Subsequently, the patient continued to receive oral prednisolone because mildly limited oculomotor 
motility persisted. In April 2011, she was free of the MG symptoms, and treatment with prednisolone 
was discontinued. 
Patient 2 
In July 1993, a 40-year-old woman with no clinically significant past history of disease experienced 
difficulty in speaking for prolonged periods. In October, she noticed nasal discharge during meals and 
had difficulty in swallowing or chewing food. In January 1994, she visited our hospital. At presentation, 
a nasal voice, bulbar paresis, and mild bilateral facial weakness were evident. The results of neurological 
examinations were negative. The results of a routine serum laboratory workup were normal. Cranial 
and cervical magnetic resonance images (MRI) were normal. The anti-acetylcholine receptor-binding 
antibody titer was 0.6 nmol/l. The edrophonium test was positive. Repetitive stimulation studies 
demonstrated a decremental response at slow stimulation rate in the orbicular muscle of the mouth and 
the abductor digiti minimi and deltoid. Mediastinal thymoma was absent on chest MRI, and MG was 
diagnosed. The patient received ambenonium (10 mg/day), and the disease severity decreased mildly. In 
June 2002, speech impairment and dysphagia developed with severe general fatigue. Oral prednisolone 
(60 mg) on alternate days was started, and the bulbar symptoms and facial muscle weakness resolved. 
Oral prednisolone was continued with tapering, with no further disease progression. The patient was 
free of general fatigue. In 2008, she gave birth without the development of MG symptoms. As of April 
2010, the patient continues to receive alternate-day oral prednisolone (10 mg). In April 2011, the oral 
prednisolone was tapered. No other symptoms of MG have developed. 
Discussion 
Our experience suggests that steroid treatment without thymectomy or other 
alternative therapies, such as plasma exchange, intravenous immunoglobulins, or 
immunosuppressive agents, can successfully resolve the symptoms of MG in selected 
patients, without myasthenic crisis or serious side effects. Many previous studies have 
reported the remission of MG in patients given long-term steroid treatment, but most 
patients received concurrent treatments, including thymectomy. One prospective 
placebo-control study of mycophenolate mofetil for 36 weeks included steroid-treated 
patients with generalized MG who had not undergone thymectomy within 12 months or 
received plasma exchange, intravenous immunoglobulins, or immunosuppressive agents 
within 3 months before randomization [2]. Steroid treatment was shown to be effective Case Rep Neurol 2011;3:239–241 
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for inducing remission of disease; beneficial effects of steroids required a dose of at least 
20 mg/day [2]. Another retrospective cohort study of 60 patients with generalized MG, 
including 10 who had received continuous steroid treatment for more than 4 years, 
reported that improvement was noted in 72% of the patients given steroids [3]. However, 
complete withdrawal of steroids was possible in only 3 patients [3]. Kawaguchi et al. [4] 
found that 34 out of 67 generalized MG patients without thymectomy responded to 
corticosteroids in at least 12 months but 32 patients had a mild generalized form of MG. 
The other 2 patients with a moderate generalized form of MG were not mentioned in 
detail [4]. The optimal dosage and treatment schedule for steroids remains undefined [5]. 
Many patients and physicians avoid using high doses of steroids and are highly motivated 
to reduce the dose whenever possible. 
We used steroid pulse therapy during childhood in patient 1 because we expected a 
rapid onset of response to steroids and because intravenous injection was relatively 
noninvasive in contrast to plasmapheresis. Steroid pulse therapy has a potential risk of 
temporarily worsening MG, referred to as ‘steroid dip’, but a study published in 2011 
showed that early aggressive high-dose intravenous methylprednisolone has the 
advantages of early improvement with less frequent steroid-related complications as 
compared with high-dose oral prednisolone therapy [6]. 
In a recent review article, S. Sathasivam recommends: ‘Steroids are useful as short-term 
immunosuppressants, and there is limited evidence for their efficacy in MG from small 
randomized trials (class II evidence)’ [7]. In the recent EFNS Guidelines for treatment of 
autoimmune neuromuscular transmission disorders, the authors state that ‘In 
observational studies, remission or marked improvement is seen in 70–80% of patients 
with MG treated with oral corticosteroids (class IV evidence), but the efficacy has not 
been studied in double-blind, placebo-controlled trials’ [8]. Our experience can raise an 
open question regarding the role of thymectomy, especially in the subgroup of patients 
without thymoma. We suggest that medical therapy is preferable to surgery in patients 
with no evidence of thymoma on CT or MRI who also have a low titer of anti-
acetylcholine receptor-binding antibody. 
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